{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Carcinoma&page=4",
    "query": {
      "condition": "Metastatic Castration-resistant Prostate Carcinoma",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 725,
    "total_pages": 73,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Carcinoma&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Castration-resistant+Prostate+Carcinoma&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T20:23:43.052Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05125016",
      "title": "A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "REGN4336",
          "type": "DRUG"
        },
        {
          "name": "REGN5678",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 228,
      "start_date": "2021-11-30",
      "completion_date": "2030-03-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 13,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Louisville, Kentucky + 8 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05125016"
    },
    {
      "nct_id": "NCT07543055",
      "title": "A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "BPX-601",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 36,
      "start_date": "2026-09-08",
      "completion_date": "2031-06-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Hackensack, New Jersey • Portland, Oregon",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07543055"
    },
    {
      "nct_id": "NCT05252390",
      "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Ovarian Cancer",
        "Ovary Cancer",
        "Cancer of Ovary",
        "Cancer of the Ovary",
        "Ovary Neoplasm",
        "Pancreatic Cancer",
        "Pancreas Cancer",
        "Cancer of Pancreas",
        "Cancer of the Pancreas",
        "Pancreas Neoplasm",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Cancer of Prostate",
        "Cancer of the Prostate",
        "Prostate Neoplasm",
        "Castrate Resistant Prostate Cancer",
        "Castration Resistant Prostatic Cancer",
        "Castration Resistant Prostatic Neoplasms",
        "Triple-negative Breast Cancer",
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Breast Cancer",
        "Breast Carcinoma",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Breast Tumor"
      ],
      "interventions": [
        {
          "name": "NUV-868",
          "type": "DRUG"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2022-03-29",
      "completion_date": "2024-07-15",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05252390"
    },
    {
      "nct_id": "NCT00004026",
      "title": "CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CT-2584",
          "type": "DRUG"
        },
        {
          "name": "chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CTI BioPharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 80,
      "start_date": "1998-12",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2020-10-19",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • New Orleans, Louisiana + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004026"
    },
    {
      "nct_id": "NCT07698535",
      "title": "Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-Resistant Prostate Adenocarcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Lutetium Lu 177 Vipivotide Tetraxetan",
          "type": "DRUG"
        },
        {
          "name": "Cell-free Circulating Tumor DNA Assay",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "PSMA PET Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Single Photon Tomography and Computed Tomography Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 64,
      "start_date": "2026-10-01",
      "completion_date": "2029-07-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07698535"
    },
    {
      "nct_id": "NCT02036918",
      "title": "Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sipuleucel-T",
          "type": "DRUG"
        },
        {
          "name": "Lymph Node Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2014-03",
      "completion_date": "2019-02-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02036918"
    },
    {
      "nct_id": "NCT01083615",
      "title": "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Castrate-Resistant Prostate Cancer",
        "Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "custirsen sodium",
          "type": "DRUG"
        },
        {
          "name": "isotonic, 0.9% sodium chloride",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Achieve Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2010-03",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2016-10-12",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 20,
      "location_summary": "La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more",
      "locations": [
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01083615"
    },
    {
      "nct_id": "NCT02649790",
      "title": "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma (RRMM)",
        "Metastatic Colorectal Cancer (mCRC)",
        "Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
        "Higher-Risk Myelodysplastic Syndrome (HR-MDS)",
        "Acute Myeloid Leukemia (AML)",
        "Newly Diagnosed Intermediate/High-Risk MDS"
      ],
      "interventions": [
        {
          "name": "KPT-8602",
          "type": "DRUG"
        },
        {
          "name": "ASTX727",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2016-01",
      "completion_date": "2024-12-23",
      "has_results": false,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 26,
      "location_summary": "Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Littleton",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649790"
    },
    {
      "nct_id": "NCT01685125",
      "title": "Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone-resistant Prostate Cancer",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "dasatinib",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 96,
      "start_date": "2012-09",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2017-07-07",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01685125"
    },
    {
      "nct_id": "NCT00394810",
      "title": "Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Panzem® NCD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CASI pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2006-11",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2008-11-25",
      "last_synced_at": "2026-10-06T20:23:43.052Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00394810"
    }
  ]
}